Table 2.

Treatment exposure

	Durvalumab + EP (n = 18)	EP (n = 16)
Median number (range) of durvalumab doses	6 (3–14)	–
Median (range) total duration of durvalumab, weeks	20.6 (10.3–75.0)	–
Platinum agent received, n (%)
Carboplatin	11 (61)	8 (50)
Cisplatin	7 (39)	8 (50)
Median number (range) of cycles of EPa	4 (3–4)	4 (2–6)
Cycles of EP received, n (%)a
≥ 4	17 (94)	13 (81)
≥ 5	0	6 (38)
6	0	6 (38)
Median (range) total duration of EP, weeksa	12.6 (10.0–14.7)	13.1 (6.7–24.7)

EP platinum-etoposide

^aBased on etoposide exposure